Talzenna® (talazoparib) – New drug approval
October 16, 2018 - Pfizer announced the FDA approval of Talzenna (talazoparib) for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.
Top